453 related articles for article (PubMed ID: 34726078)
21. Co-administration of proton pump inhibitors delays elimination of plasma methotrexate in high-dose methotrexate therapy.
Suzuki K; Doki K; Homma M; Tamaki H; Hori S; Ohtani H; Sawada Y; Kohda Y
Br J Clin Pharmacol; 2009 Jan; 67(1):44-9. PubMed ID: 19076159
[TBL] [Abstract][Full Text] [Related]
22. Risk of cutaneous adverse reactions associated with allopurinol or febuxostat in real-world patients: A nationwide study.
Lin CW; Huang WI; Chao PH; Chen WW; Hsiao FY
Int J Clin Pract; 2019 May; 73(5):e13316. PubMed ID: 30681751
[TBL] [Abstract][Full Text] [Related]
23. Comparing Cardiovascular Safety of Febuxostat and Allopurinol in the Real World: A Population-Based Cohort Study.
Su CY; Shen LJ; Hsieh SC; Lin LY; Lin FJ
Mayo Clin Proc; 2019 Jul; 94(7):1147-1157. PubMed ID: 31272565
[TBL] [Abstract][Full Text] [Related]
24. Comparison of efficacy and safety between febuxostat and allopurinol in early post-renal transplant recipients with new onset of hyperuricemia.
Shen X; Li J; Fu Q; Liu L; Gao X; Chen X; Chen P; Wang C
J Clin Pharm Ther; 2019 Apr; 44(2):318-326. PubMed ID: 30582178
[TBL] [Abstract][Full Text] [Related]
25. Comparative effectiveness of urate lowering with febuxostat versus allopurinol in gout: analyses from large U.S. managed care cohort.
Singh JA; Akhras KS; Shiozawa A
Arthritis Res Ther; 2015 May; 17(1):120. PubMed ID: 25963969
[TBL] [Abstract][Full Text] [Related]
26. The BCRP inhibitor febuxostat enhances the effect of nilotinib by regulation of intracellular concentration.
Ito F; Miura M; Fujioka Y; Abumiya M; Kobayashi T; Takahashi S; Yoshioka T; Kameoka Y; Takahashi N
Int J Hematol; 2021 Jan; 113(1):100-105. PubMed ID: 33025461
[TBL] [Abstract][Full Text] [Related]
27. Febuxostat for treating chronic gout.
Tayar JH; Lopez-Olivo MA; Suarez-Almazor ME
Cochrane Database Syst Rev; 2012 Nov; 11(11):CD008653. PubMed ID: 23152264
[TBL] [Abstract][Full Text] [Related]
28. Cardiovascular effects of urate-lowering therapies in patients with chronic gout: a systematic review and meta-analysis.
Zhang T; Pope JE
Rheumatology (Oxford); 2017 Jul; 56(7):1144-1153. PubMed ID: 28379501
[TBL] [Abstract][Full Text] [Related]
29. The Association of Febuxostat Compared With Allopurinol on Blood Pressure and Major Adverse Cardiac Events Among Adult Patients With Hyperuricemia: A Meta-analysis.
Barrientos-Regala M; Macabeo RA; Ramirez-Ragasa R; Pestaño NS; Punzalan FER; Tumanan-Mendoza B; Castillo RR
J Cardiovasc Pharmacol; 2020 Oct; 76(4):461-471. PubMed ID: 32675751
[TBL] [Abstract][Full Text] [Related]
30. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial.
Schumacher HR; Becker MA; Wortmann RL; Macdonald PA; Hunt B; Streit J; Lademacher C; Joseph-Ridge N
Arthritis Rheum; 2008 Nov; 59(11):1540-8. PubMed ID: 18975369
[TBL] [Abstract][Full Text] [Related]
31. Diabetes and gout: efficacy and safety of febuxostat and allopurinol.
Becker MA; MacDonald PA; Hunt BJ; Jackson RL
Diabetes Obes Metab; 2013 Nov; 15(11):1049-55. PubMed ID: 23683134
[TBL] [Abstract][Full Text] [Related]
32. [Febuxostat or allopurinol in patients with gout : Cardiovascular Safety of Febuxostat and Allopurinol in Patients with Gout and Cardiovascular Morbidities (CARES)].
Alten R; Mischkewitz M; Nitschmann S
Internist (Berl); 2020 May; 61(5):530-532. PubMed ID: 32130437
[No Abstract] [Full Text] [Related]
33. Comparison of efficacy and safety of urate-lowering therapies for hyperuricemic patients with gout: a meta-analysis of randomized, controlled trials.
Fan M; Liu J; Zhao B; Wu X; Li X; Gu J; Schlesinger N
Clin Rheumatol; 2021 Feb; 40(2):683-692. PubMed ID: 32654080
[TBL] [Abstract][Full Text] [Related]
34. Effects of intensive urate lowering therapy with febuxostat in comparison with allopurinol on pulse wave velocity in patients with gout and increased cardiovascular risk: the FORWARD study.
Desideri G; Rajzer M; Gerritsen M; Nurmohamed MT; Giannattasio C; Tausche AK; Borghi C
Eur Heart J Cardiovasc Pharmacother; 2022 May; 8(3):236-242. PubMed ID: 33410912
[TBL] [Abstract][Full Text] [Related]
35. Febuxostat: a selective xanthine-oxidase/xanthine-dehydrogenase inhibitor for the management of hyperuricemia in adults with gout.
Ernst ME; Fravel MA
Clin Ther; 2009 Nov; 31(11):2503-18. PubMed ID: 20109996
[TBL] [Abstract][Full Text] [Related]
36. Effectiveness of febuxostat in patients with allopurinol-refractory hyperuricemic chronic kidney disease
.
Kwak CH; Sohn M; Han N; Cho YS; Kim YS; Oh JM
Int J Clin Pharmacol Ther; 2018 Jul; 56(7):321-327. PubMed ID: 29750634
[TBL] [Abstract][Full Text] [Related]
37. The major cardiovascular events of febuxostat versus allopurinol in treating gout or asymptomatic hyperuricemia: a systematic review and meta-analysis.
Wang M; Zhang Y; Zhang M; Li H; Wen C; Zhao T; Xie Z; Sun J
Ann Palliat Med; 2021 Oct; 10(10):10327-10337. PubMed ID: 34498481
[TBL] [Abstract][Full Text] [Related]
38. Drug Interaction Between Febuxostat and Thiopurine Antimetabolites: A Review of the FDA Adverse Event Reporting System and Medical Literature.
Logan JK; Wickramaratne Senarath Yapa S; Harinstein L; Saluja B; Muñoz M; Sahajwalla C; Neuner R; Seymour S
Pharmacotherapy; 2020 Feb; 40(2):125-132. PubMed ID: 31885095
[TBL] [Abstract][Full Text] [Related]
39. Hepatic Safety of Febuxostat Compared with Allopurinol in Gout Patients with Fatty Liver Disease.
Lee JS; Won J; Kwon OC; Lee SS; Oh JS; Kim YG; Lee CK; Yoo B; Hong S
J Rheumatol; 2019 May; 46(5):527-531. PubMed ID: 30442825
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of febuxostat for prevention of tumor lysis syndrome in patients with malignant tumors receiving chemotherapy: a phase III, randomized, multi-center trial comparing febuxostat and allopurinol.
Tamura K; Kawai Y; Kiguchi T; Okamoto M; Kaneko M; Maemondo M; Gemba K; Fujimaki K; Kirito K; Goto T; Fujisaki T; Takeda K; Nakajima A; Ueda T
Int J Clin Oncol; 2016 Oct; 21(5):996-1003. PubMed ID: 27017611
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
